| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |